News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forest Laboratories, Inc. (FRX) Launches STRIDE Patient Support Program For COPD Franchise Products Tudorza® Pressair® And Daliresp®


2/24/2014 9:26:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced the launch of the STRIDE (Start Treatment, Real-time Information, Disease Education) patient support program to help those prescribed Tudorza® Pressair® (aclidinium bromide inhalation powder) or Daliresp® (roflumilast) by answering questions they may have about their chronic obstructive pulmonary disease (COPD) treatment. COPD is a progressive and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES